Corient Private Wealth LLC Sells 10,106 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Corient Private Wealth LLC decreased its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 18.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,520 shares of the company's stock after selling 10,106 shares during the quarter. Corient Private Wealth LLC's holdings in Henry Schein were worth $3,150,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Brandes Investment Partners LP grew its position in Henry Schein by 10.9% in the fourth quarter. Brandes Investment Partners LP now owns 9,367 shares of the company's stock worth $648,000 after acquiring an additional 918 shares in the last quarter. Essential Planning LLC. bought a new stake in Henry Schein in the fourth quarter worth $934,000. Sequoia Financial Advisors LLC increased its position in Henry Schein by 7.2% during the fourth quarter. Sequoia Financial Advisors LLC now owns 6,109 shares of the company's stock worth $423,000 after buying an additional 412 shares during the last quarter. HighTower Advisors LLC raised its holdings in Henry Schein by 242.9% during the fourth quarter. HighTower Advisors LLC now owns 43,347 shares of the company's stock valued at $3,000,000 after buying an additional 30,706 shares in the last quarter. Finally, AGF Management Ltd. acquired a new stake in shares of Henry Schein in the fourth quarter worth about $796,000. Institutional investors and hedge funds own 96.62% of the company's stock.

Insiders Place Their Bets

In related news, CEO Bradford C. Connett sold 4,036 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the transaction, the chief executive officer now owns 62,688 shares of the company's stock, valued at approximately $4,460,251.20. This trade represents a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the transaction, the director now owns 24,805 shares of the company's stock, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

Remove Ads

Henry Schein Stock Performance

Shares of NASDAQ HSIC traded up $0.37 during trading hours on Wednesday, reaching $69.75. The stock had a trading volume of 922,133 shares, compared to its average volume of 1,504,998. The company has a market cap of $8.66 billion, a price-to-earnings ratio of 28.70, a PEG ratio of 2.13 and a beta of 0.90. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.49. The business's fifty day moving average is $74.79 and its two-hundred day moving average is $72.65.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.66 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HSIC. Bank of America raised Henry Schein from an "underperform" rating to a "buy" rating and increased their price objective for the company from $69.00 to $84.00 in a report on Monday, January 6th. Mizuho began coverage on shares of Henry Schein in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $75.00 price objective for the company. Wells Fargo & Company started coverage on shares of Henry Schein in a report on Friday, February 14th. They set an "equal weight" rating and a $80.00 price objective for the company. UBS Group cut their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research report on Wednesday, February 26th. Finally, Barrington Research reaffirmed an "outperform" rating and issued a $90.00 price target on shares of Henry Schein in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Henry Schein has a consensus rating of "Moderate Buy" and a consensus target price of $81.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.